ArticleBMC infectious diseases2025
HPV genotype distribution and cervical lesions in Chongqing: a comprehensive analysis of 229,770 females (2015‒2023).
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Association of PAX1/JAM3 gene methylation, HR-HPV, and TCT with high-grade cervical lesions in a high-risk cohort: a multinomial logistic regression analysis.BMC women's health · 2026Article
- An epidemiological survey of HPV infection among women in Southern Hebei, China.Virology journal · 2026Article
- HPV52 predominates in cervical infections and precancerous lesions in Chongqing, China: a 6-year study linking genotypes to vaginal microecology.Frontiers in public health · 2026Article
- Clinical significance ofFrontiers in cellular and infection microbiology · 2026Article
- From HPV genotypes to cervical lesion burden: public health-relevant heterogeneity across 1.29 million screening records in Guangdong, China.Frontiers in public health · 2026Article
- Predictive Factors for Cervical Intraepithelial Neoplasia in Women with Abnormal Cytology According to Human Papillomavirus Genotype: An Observational Study.International journal of molecular sciences · 2025Observational
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundCervical cancer ranks fourth among cancers in women globally, with over 300,000 deaths annually worldwide. Persistent high-risk HPV (HR-HPV) infection is the main cause of cervical cancer. The World Health Organization (WHO) recommends human papillomavirus (HPV) DNA testing for cervical cancer screening. This study analyses the distribution of HPV genotypes and further investigates their association with the severity of cervical lesions, aiming to develop prevention and screening strategies for cervical cancer.
methodsA retrospective study was conducted on 229,770 females who underwent HPV DNA testing at The First Affiliated Hospital of Chongqing Medical University between January 2015 and December 2023 to assess the epidemiological distribution of HPV genotypes. In addition, HPV genotypes were further analysed in cervical samples from 749 patients in 2023 who were screened for HPV DNA and had available histological diagnoses. HPV genotyping was performed using capillary electrophoresis analysis.
resultsThe overall HPV prevalence was 21.41% among 229,770 patients over the past nine years. Among hr-HPV types, the five most common genotypes were HPV52 (4.55%), HPV16 (3.44%), HPV58 (2.94%), HPV56 (1.33%), and HPV39 (1.32%). Single HPV infection (16.89%) was more common than multiple infections. HPV prevalence exhibited a bimodal distribution, peaking in the under-30 and over-60 age groups. Among 749 HPV-positive patients, the cervical cancer group had the highest median age of 55(interquartile range, 48‒65) years. HPV16 showed the highest prevalence across the different degrees of cervical lesions, followed by HPV52 and HPV58. HR-HPV was found in nearly all cervical cancer cases, with a prevalence of 88.43%, 98.55%, and 97.39% in the low-grade squamous intraepithelial lesion, high-grade squamous intraepithelial lesion, and cervical cancer groups, respectively.
conclusionsThe distribution of HPV genotypes varies by year and age group. HPV16, HPV18, HPV52, and HPV58 are the predominant genotypes detected in high-grade cervical lesions and cervical cancer groups. Given the high prevalence in these lesions, vaccines incorporating HPV52 and HPV58 may offer enhanced protection. Based on local epidemiological data, adaptable vaccination programs and effective screening are essential for preventing and reducing the risk of cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.